InvestorsHub Logo
Followers 37
Posts 4190
Boards Moderated 0
Alias Born 10/18/2016

Re: None

Wednesday, 11/08/2017 12:43:56 PM

Wednesday, November 08, 2017 12:43:56 PM

Post# of 28488
Compensated Awareness Post View Disclaimer
PBIO Progresses in Global Life Sciences Industry

Pressure BioSciences, Inc. (OTCQB: PBIO) is engaged in the development and sale of innovative solutions for the worldwide life sciences industry. The company is advancing in the industry, with its patented high pressure cycling technology. PBIO also recently received patents for its Ultra Shear Technology. An article discussing this reads: “Pressure BioSciences, which completed 2016 with $2 million in sales with only one salesperson on board, has recently added five more people to the sales staff — and the team is diligently working to continue the company’s progress in the industry. Its newest table-top, high-pressure instrument is a finalist in the 2017 R&D 100 Awards, which are often referred to as the “Oscars of Innovation”. Furthermore, key opinion leaders around the globe are beginning to recognize the Barocycler 2320EXT instrument as a “must have” for laboratory research because of the many advantages the instrument has over its competitors, including a new USB output port where data generated by the instrument can be downloaded, making it a useful tool for FDA-required testing in biopharma quality control, a brand new application.”

To view the full article, visit http://nnw.fm/f4Wkn

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (“PBI”) (OTCQB: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. The company’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. PBI’s primary focus is in the development of PCT-based products for biomarker and target discovery, drug development and design, bio-therapeutics characterization, soil & plant biology, forensics, and counter-bioterror applications. Major new focal market opportunities are emerging in the use of the company’s patented, scalable, high-efficiency Ultra Shear Technology (“UST”) to create stable nanoemulsions of otherwise immiscible fluids (such as oils and water), and to prepare higher quality, homogenized, extended shelf-life or room temperature stable, low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. For more information, visit the company’s website at www.pressurebiosciences.com.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PBIO News